Literature DB >> 9824478

Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production.

H Akimoto1, H Kaneko, I Sekigawa, H Hashimoto, Y Kaneko, N Yamamoto.   

Abstract

We recently found that human immunodeficiency virus (HIV)-2 envelope glycoprotein, but not that of HIV-1, could bind to CD4 and CD8 molecules on T cells, and that the binding site of HIV-2 envelope glycoprotein was located on the alpha-chain (but not the beta-chain) of CD8. This study showed that the binding of HIV-2 envelope glycoprotein could induce phosphorylation of protein tyrosine kinase p56lck in CD8+ T cells. We also found that production of beta-chemokines in response to HIV-2 envelope glycoprotein was significantly higher than that in response to HIV-1 envelope glycoprotein, and that CD8+ T cells were the main source of beta-chemokines production among the T-cell population. These findings indicate the possibility that the binding of envelope glycoprotein to CD8 molecules are related to signal transduction into CD8+ T cells and the resultant beta-chemokine production in HIV-2 infection. Our results may help to explain the differences in disease manifestations between HIV-1 and HIV-2, including the lower virulence of HIV-2 and the longer survival of HIV-2-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824478      PMCID: PMC1364307          DOI: 10.1046/j.1365-2567.1998.00537.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  gp120 ligation of CD4 induces p56lck activation and TCR desensitization independent of TCR tyrosine phosphorylation.

Authors:  F Goldman; W A Jensen; G L Johnson; L Heasley; J C Cambier
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 4.  Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells.

Authors:  J A Levy; C E Mackewicz; E Barker
Journal:  Immunol Today       Date:  1996-05

5.  Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals.

Authors:  J Eugen-Olsen; A K Iversen; P Garred; U Koppelhus; C Pedersen; T L Benfield; A M Sorensen; T Katzenstein; E Dickmeiss; J Gerstoft; P Skinhøj; A Svejgaard; J O Nielsen; B Hofmann
Journal:  AIDS       Date:  1997-03       Impact factor: 4.177

6.  Simian immunodeficiency virus infection of CD8+ lymphocytes in vivo.

Authors:  G A Dean; G H Reubel; N C Pedersen
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

Review 8.  Lessons from the second AIDS virus, HIV-2.

Authors:  R Marlink
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

Review 9.  Cell surface down-modulation of CD4 after infection by HIV-1.

Authors:  R Geleziunas; S Bour; M A Wainberg
Journal:  FASEB J       Date:  1994-06       Impact factor: 5.191

10.  CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

Authors:  M J Endres; P R Clapham; M Marsh; M Ahuja; J D Turner; A McKnight; J F Thomas; B Stoebenau-Haggarty; S Choe; P J Vance; T N Wells; C A Power; S S Sutterwala; R W Doms; N R Landau; J A Hoxie
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.